Opus Genetics, Inc. (IRD) Tops Q2 EPS by 7c

Opus Genetics, Inc. (NASDAQ: IRD) reported Q2 EPS of ($0.12), $0.07 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $2.88 million versus the consensus estimate of $4.04 million.

For earnings history and earnings-related data on Opus Genetics, Inc. (IRD) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results
• Reading (RDI) Tops Q2 EPS by 4c